What is Aditxt Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aditxt's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.01.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Aditxt couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for Aditxt's Cash-to-Debt or its related term are showing as below:
ADTX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.49 Max: No Debt
Current: 0.01
During the past 7 years, Aditxt's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 0.49.
Aditxt Cash-to-Debt Historical Data
The historical data trend for Aditxt's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Aditxt Cash-to-Debt Chart
|
Aditxt Annual Data
|
|
Trend |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
0.02 |
5.72 |
1.67 |
0.82 |
0.01 |
|
Aditxt Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.07 |
0.02 |
0.26 |
0.01 |
0.01 |
Competitive Comparison of Aditxt's Cash-to-Debt
For the Biotechnology subindustry, Aditxt's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aditxt's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aditxt's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Aditxt's Cash-to-Debt falls into.
Aditxt Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Aditxt's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Aditxt's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aditxt (Aditxt) Business Description
Traded in Other Exchanges
N/A
Address
737 North Fifth Street, Suite 200, Richmond, VA, USA, 23219
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
Executives
| Charles Athle Nelson |
director |
11-F, BUILDING 12, SUNKING PLAZA, GAOJIAO ROAD, HANGZHOU, ZHEJIANG F4 311122 |
| Bnp Paribas Securities Corp |
10 percent owner |
787 SEVENTH AVE, NEW YORK NY 10019 |
| Matthew Shatzkes |
officer: Chief Legal Officer and GC |
737 N. FIFTH STREET, SUITE 200, RICHMOND VA 23219 |
| Lauren Chung |
director |
1620 BEACON STREET, OXNARD CA 93033 |
| Thomas J Farley |
officer: PRINCIPAL ACCOUNTING OFFICER |
2569 WYANDOTTE ST., SUITE 101, MOUNTAIN VIEW CA 94043 |
| Jeffrey W. Runge |
director |
C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401 |
| Rowena Albanna |
officer: CHIEF OPERATING OFFICER |
11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354 |
| Rosland Fisher Mcleod |
director |
11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354 |
| Pankovcin Corinne |
officer: CHIEF FINANCIAL OFFICER |
BUSINESS DEVELOPMENT CORP OF AMERICA, 405 PARK AVENUE, 14TH FLOOR, NEW YORK NY 10022 |
| Laura E Anthony |
director |
LAURA ANTHONY, 120 S. OLIVE AVE, WEST PALM BEACH FL 33401 |
| Namvar Kiaie |
director |
11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354 |
| Brian Michael Brady |
director |
11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354 |
| Amro A. Albanna |
director, officer: CHIEF EXECUTIVE OFFICER |
871 MARLBOROUGH AVENUE, SUITE 100, RIVERSIDE CA 92507 |
| Shahrokh Shabahang |
director, officer: CHIEF INNOVATION OFFICER |
11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354 |
Aditxt (Aditxt) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADTX has been successfully added to your